See the DrugPatentWatch profile for Flecainide
Flecainide belongs to a class of antiarrhythmic medications known as Class Ic antiarrhythmics [1]. These drugs are primarily used to treat and prevent certain types of abnormal heart rhythms, or arrhythmias [2].
How Do Class Ic Antiarrhythmics Work?
Class Ic antiarrhythmics, including flecainide, work by blocking fast sodium channels in the heart muscle cells [1][3]. This action slows down the electrical conduction within the heart, particularly in the atria and ventricles, which helps to stabilize the heart rhythm [3]. They have minimal effects on the duration of the electrical impulse or the heart's refractory period compared to other antiarrhythmic classes [1].
What Conditions Does Flecainide Treat?
Flecainide is indicated for the prevention of supraventricular tachycardias (fast heart rhythms originating above the ventricles), such as atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia associated with accessory pathways [2][4]. It is also used to maintain normal sinus rhythm in patients with atrial fibrillation or atrial flutter, and for the prevention of paroxysmal atrial fibrillation [2][4].
Are There Risks Associated with Flecainide?
Yes, flecainide carries significant risks, particularly in patients with underlying structural heart disease [2][5]. It has been associated with an increased risk of mortality and non-fatal cardiovascular events, such as cardiac arrest and death, in patients with prior myocardial infarction or other heart disease [5]. Therefore, its use is generally restricted to patients without significant structural heart disease [2]. Other potential side effects include new or worsened arrhythmias (proarrhythmia), dizziness, visual disturbances, and nausea [4].
How Does Flecainide Compare to Other Antiarrhythmics?
Flecainide is distinct from other classes of antiarrhythmics due to its potent sodium channel blockade with minimal effect on repolarization [1]. For example, Class Ia drugs also block sodium channels but have significant effects on repolarization, while Class Ib drugs primarily affect sodium channels during faster heart rates. Class II antiarrhythmics (beta-blockers) affect the sympathetic nervous system, and Class III antiarrhythmics (like amiodarone) primarily prolong the action potential duration [1].
What is the Patent Status of Flecainide?
The original patents for flecainide have long expired, allowing for the production of generic versions of the drug [6]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would detail the patent landscape for flecainide and any related innovations [6].
Who Manufactures Flecainide?
Flecainide is manufactured by various pharmaceutical companies as a generic medication. The brand-name version, Tambocor, was originally developed by 3M Pharmaceuticals [4].
When is Flecainide Prescribed?
Flecainide is typically prescribed by a cardiologist or electrophysiologist for patients experiencing symptomatic supraventricular arrhythmias or atrial fibrillation who do not have significant structural heart disease [2][4]. It is often used when other treatments have failed or are not suitable [4].
Sources:
[1] https://www.drugpatentwatch.com/drug-class/class-ic-antiarrhythmics
[2] https://www.drugpatentwatch.com/drugs/flecainide
[3] https://www.drugpatentwatch.com/drug-mechanism/sodium-channel-blocker
[4] https://www.rxlist.com/tambocor-drug.htm
[5] https://www.ahajournals.org/doi/10.1161/01.cir.84.4.1610
[6] https://www.drugpatentwatch.com/flecainide